Johns Hopkins Researchers Report Early Success in Preventing Pancreatic Cancer
Pancreatic cancer has long been one of medicine’s most feared diagnoses. It is often called a silent killer because it can grow for years without causing symptoms, allowing it to spread before it is discovered. By the time many patients learn they have the disease, treatment options are limited and survival rates are poor. That reality has made prevention one of the biggest unanswered challenges in cancer research.
Now, scientists at the Johns Hopkins Kimmel Cancer Center believe they may have taken an important first step toward changing that future.
Researchers have reported encouraging results from an early clinical trial of an experimental vaccine designed to prevent pancreatic cancer before tumors ever develop. While the study is still in its early stages, the findings suggest that the immune system can be trained to recognize and destroy dangerous cells before they become cancer.
For a disease that remains largely incurable once it reaches an advanced stage, the implications could be enormous.
A New Strategy Against a Deadly Disease
Unlike traditional cancer treatments that attack tumors after they form, this vaccine is designed to intercept pancreatic cancer during its earliest stages.
The research focuses on people who have inherited genetic mutations that place them at exceptionally high risk for developing pancreatic cancer. These individuals often undergo years of surveillance, with doctors watching for pancreatic cysts or precancerous lesions that could eventually become malignant.
Even with careful monitoring, the outlook remains uncertain.
“Individuals at high risk due to hereditary predisposition… usually undergo surveillance to monitor for changes over time,” said Dr. Neeha Zaidi, associate professor of oncology at Johns Hopkins Medicine and co-senior author of the study.
If suspicious changes are discovered, surgery is often the only option. Unfortunately, surgery does not eliminate the danger.
“The chances of recurrence are up to 80%, and many precursor lesions to pancreatic cancer are microscopic and thus undetectable by imaging,” Zaidi explained.
That challenge inspired researchers to ask a different question. Instead of waiting for cancer to appear, could the immune system be taught to eliminate dangerous cells before tumors ever develop?
Targeting the KRAS Mutation
The experimental vaccine, known as mKRAS-VAX, targets mutations in the KRAS gene, one of the most important genetic drivers of pancreatic cancer.
More than 90 percent of pancreatic cancers contain KRAS mutations, and those same mutations frequently appear in precancerous pancreatic lesions long before cancer develops.
The vaccine is peptide based and targets the six most common KRAS mutations associated with pancreatic cancer. Its goal is to train immune cells to recognize these abnormal proteins and destroy cells carrying the mutations before they can become cancerous.
Rather than reacting to cancer after it appears, researchers hope to stop the disease before it ever gains a foothold.
Inside the Phase I Clinical Trial
The Phase I study enrolled 20 participants who carried an inherited genetic predisposition to pancreatic cancer and who also had pancreatic abnormalities identified through imaging.
Participants received four injections of the vaccine over a 13 week period, with doses administered during weeks one, three, five and thirteen.
Researchers then closely monitored participants through blood testing and medical imaging for a median follow up period of 16.5 months.
The primary purpose of the study was to determine whether the vaccine was safe and whether it successfully activated the immune system.
The results exceeded expectations.
Eighteen of the twenty participants, or 90 percent, developed a significant immune response against the targeted KRAS mutations.
Investigators measured a median 18.2 fold increase in KRAS specific T cell activity, showing that the vaccine successfully activated immune cells capable of recognizing the mutations associated with pancreatic cancer.
Even more encouraging, memory T cells remained detectable in patients for as long as two years after vaccination, suggesting the immune system could maintain long term protection.
Zaidi called the durable immune response especially important.
“This long-lasting response is particularly noteworthy when assessing for possible interception of cancer, which requires long-lasting immunity.”
Remarkable Early Findings
Although the study was not designed to prove the vaccine prevents pancreatic cancer, the early clinical observations were striking.
After 16.5 months of follow up, none of the participants developed pancreatic cancer or high risk pancreatic lesions requiring surgery.
Researchers also examined changes in pancreatic cysts among participants.
Five patients experienced complete disappearance of small pancreatic cysts, while three others showed partial regression. The remaining cysts remained stable throughout the study.
Overall, 37.5 percent of vaccinated participants experienced shrinkage or elimination of pancreatic cysts, compared with only 6.8 percent among unvaccinated individuals included for comparison.
The vaccine also demonstrated a favorable safety profile.
All treatment related side effects were classified as mild to moderate. The most common reactions included soreness at the injection site, fatigue, chills and flu like symptoms, all of which resolved without requiring treatment.
An Important Proof of Concept
Researchers emphasize that this was a small Phase I safety trial, not a definitive study proving cancer prevention.
The limited number of participants and relatively short follow up period mean much larger clinical trials will be needed before doctors can conclude that the vaccine prevents pancreatic cancer.
Even so, investigators believe the results represent an important milestone.
“Overall, this study represents the first proof of concept for the use of vaccines for interception of pancreatic cancer in human patients,” Zaidi said.
The research builds upon an earlier trial in patients who had already undergone surgery for pancreatic cancer. In that previous study, patients who generated strong immune responses remained disease free for at least five years, encouraging researchers to investigate whether the same approach could work even earlier in the disease process.
“We thought if we can see an immune response in patients with cancer, the vaccine should work even better in people who are at higher risk because of a family history, gene alteration or cyst on the pancreas,” Zaidi explained.
Johns Hopkins researchers have already launched another clinical study that will examine how vaccine generated immune cells interact directly with precancerous pancreatic tissue.
A Glimpse of a Different Future
Pancreatic cancer remains one of the deadliest forms of cancer, with more than 67,000 Americans expected to be diagnosed this year and nearly 53,000 projected to die from the disease.
Those statistics underscore why prevention could become one of the most significant advances in the fight against pancreatic cancer.
“This is just the beginning, but the findings suggest that the immune system is getting activated,” said Dr. Elizabeth Jaffee, deputy director of the Johns Hopkins Kimmel Cancer Center.
“We have more work to do, but this is a good start aimed at prevention, which no one had thought about doing before.”
If future studies confirm these early findings, mKRAS-VAX could become the first vaccine designed to prevent pancreatic cancer before tumors develop. For patients facing one of the most aggressive and difficult cancers in medicine, that possibility represents something rarely associated with pancreatic cancer: genuine hope.
:::
